Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?Zacks Investment Research • 10/10/25
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeGlobeNewsWire • 10/09/25
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeBusiness Wire • 10/09/25
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's DiseasePRNewsWire • 10/06/25
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in ChinaGlobeNewsWire • 09/28/25
Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/24/25
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in AustraliaGlobeNewsWire • 09/24/25
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline CandidatesGlobeNewsWire • 09/18/25
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in EuropeGlobeNewsWire • 09/17/25
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track StatusGlobeNewsWire • 09/02/25
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet SyndromeGlobeNewsWire • 09/02/25
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet SyndromeBusiness Wire • 09/02/25
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and MoreBarrons • 09/02/25
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of LeqembiZacks Investment Research • 09/01/25
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's TreatmentInvestors Business Daily • 08/29/25